Oncology Knowledge Base

Timeline Browse

Subtype:

Stage:

Loading filters...

50 results(scroll for more)

HER2+ (HR-)both2026

HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies.

Goyette MA et al. Cancer Discov. 2026

generalAdvanced / Metastatic Breast Cancer2026

Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

Chiddarwar T et al. Breast Cancer Res Treat. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Jhaveri KL et al. Ann Oncol. 2026

HR+/HER2-both2026

Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.

Rubin SM et al. Cancer Res. 2026

HER2+ (HR-)both2026

Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study.

Molnar AO et al. Breast Cancer Res Treat. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer-comparing real-world outcomes in England to the MONARCH-2 trial.

Anderson J et al. Br J Cancer. 2026

HER2+ (HR-)both2026

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation.

Bharadwaj S et al. Clin Cancer Res. 2026

generalEarly Breast Cancer2026

Clinical Validation of Digital PCR-Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results.

Roseshter T et al. Clin Cancer Res. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.

Herzog SK et al. Cancer Res. 2026

generalEarly Breast Cancer2026

Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy.

Tavares GM et al. Breast Cancer Res Treat. 2026

HR+/HER2-both2026

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Conte B et al. Clin Cancer Res. 2026

genomicboth2026

Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition.

Sottnik JL et al. Cancer Res. 2026

HR+/HER2-both2026

ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6/ERK signaling in ER-positive breast cancer.

Kye YH et al. Br J Cancer. 2026

generalAdvanced / Metastatic Breast Cancer2026

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.

Rugo HS et al. Breast Cancer Res Treat. 2026

TNBCAdvanced / Metastatic Breast Cancer2026

Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer.

Shaaban AE et al. Br J Cancer. 2026

generalboth2026

Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.

Park CS et al. JAMA Oncol. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Hörner M et al. Breast Cancer Res Treat. 2026

TNBCAdvanced / Metastatic Breast Cancer2026

CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.

Poissonnier A et al. Clin Cancer Res. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Scafetta R et al. Eur J Cancer. 2026

HER2+ (HR-)both2026

Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.

Gao A et al. Cancer Res. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Rb expression in metastatic ER-positive breast cancer: implications for precision oncology.

Morrar D et al. Breast Cancer Res Treat. 2026

HR+/HER2+ (Triple Positive)Early Breast Cancer2026

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.

de Moura Leite L et al. Breast Cancer Res Treat. 2026

HR+/HER2-both2026

Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.

Robertson JFR et al. J Clin Oncol. 2026

generalEarly Breast Cancer2026

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Masuda N et al. Breast Cancer Res Treat. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.

Wang J et al. JAMA Oncol. 2026

generalAdvanced / Metastatic Breast Cancer2026

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

Gong C et al. ESMO Open. 2026

TNBCAdvanced / Metastatic Breast Cancer2026

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.

Rugo HS et al. ESMO Open. 2026

HER2+ (HR-)both2026

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results.

Murthy RK et al. Nat Cancer. 2026

TNBCEarly Breast Cancer2026

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Andrade MO et al. Breast Cancer Res Treat. 2026

HR+/HER2-both2026

ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.

Jing F et al. Breast Cancer Res Treat. 2026

TNBCEarly Breast Cancer2026

Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

Su A et al. NPJ Breast Cancer. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Jhaveri K et al. Clin Cancer Res. 2026

generalboth2026

HIF-1-regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer.

Zhou C et al. NPJ Breast Cancer. 2026

HER2+ (HR-)Advanced / Metastatic Breast Cancer2026

Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.

Song PN et al. Breast Cancer Res Treat. 2026

generalAdvanced / Metastatic Breast Cancer2026

OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer.

Xu B et al. Ann Oncol. 2026

HR+/HER2-Early Breast Cancer2026

Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies.

Nardin S et al. Eur J Cancer. 2026

TNBCboth2026

The SDC1-ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment that Drives Tumor Radioresistance.

Hou X et al. Cancer Res. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

Jacob S et al. ESMO Open. 2026

genomicAdvanced / Metastatic Breast Cancer2026

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Tung NM et al. J Clin Oncol. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Hurvitz SA et al. J Clin Oncol. 2026

TNBCAdvanced / Metastatic Breast Cancer2026

A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.

Giordano A et al. Breast Cancer Res Treat. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care.

Brufsky AM et al. Breast Cancer Res Treat. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.

Jhaveri K et al. ESMO Open. 2026

generalboth2026

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Li T et al. J Clin Oncol. 2026

HR+/HER2-Early Breast Cancer2026

Heterogeneity and immune microenvironment of early invasive estrogen receptor-positive breast cancer reveal an immune-rich subset.

Jain D et al. NPJ Breast Cancer. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.

Curigliano G et al. Ann Oncol. 2026

TNBCAdvanced / Metastatic Breast Cancer2026

KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Rugo HS et al. Clin Cancer Res. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

Tucatinib Gives PFS Boost for Metastatic Breast Cancer.

Cancer Discov. 2026

HR+/HER2-Advanced / Metastatic Breast Cancer2026

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Blanc-Durand F et al. Clin Cancer Res. 2026

TNBCEarly Breast Cancer2026

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Gouveia MC et al. NPJ Breast Cancer. 2026

HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies.

Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.

Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study.

Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer-comparing real-world outcomes in England to the MONARCH-2 trial.

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation.

Clinical Validation of Digital PCR-Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results.

Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.

Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy.

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition.

ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6/ERK signaling in ER-positive breast cancer.

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.

Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer.

Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.

Rb expression in metastatic ER-positive breast cancer: implications for precision oncology.

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.

Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results.

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.

Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

HIF-1-regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer.

Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.

OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer.

Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies.

The SDC1-ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment that Drives Tumor Radioresistance.

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care.

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Heterogeneity and immune microenvironment of early invasive estrogen receptor-positive breast cancer reveal an immune-rich subset.

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.

KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Tucatinib Gives PFS Boost for Metastatic Breast Cancer.

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.